Literature DB >> 7662964

Classification of Fanconi anemia patients by complementation analysis: evidence for a fifth genetic subtype.

H Joenje1, J R Lo ten Foe, A B Oostra, C G van Berkel, M A Rooimans, T Schroeder-Kurth, R D Wegner, J J Gille, M Buchwald, F Arwert.   

Abstract

Fanconi anemia (FA) is an autosomal recessive disease with diverse clinical symptoms, life-threatening progressive panmyelopathy, and cellular hypersensitivity to cross-linking agents. Currently, 4 genetic subtypes or complementation groups (FA-A through FA-D) have been distinguished among 7 unrelated FA patients. We report the use of genetically marked FA lymphoblastoid cell lines representing each of the 4 presently known complementation groups to classify 13 unrelated FA patients through cell fusion and complementation analysis. Twelve cell lines failed to complement cross-linker sensitivity in fusion hybrids with only 1 of the 4 reference cell lines and could thus be unambiguously classified as FA-A (7 patients), FA-C (4 patients), or FA-D (1 patient). One cell line complemented all 4 reference cell lines and therefore represents a new complementation group, designated FA-E. These results imply that at least 5 genes appear to be involved in a pathway that, when defective, causes bone marrow failure in FA patients.

Entities:  

Mesh:

Year:  1995        PMID: 7662964

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Complementation analysis in Fanconi anemia: assignment of the reference FA-H patient to group A.

Authors:  H Joenje; M Levitus; Q Waisfisz; A D'Andrea; I Garcia-Higuera; T Pearson; C G van Berkel; M A Rooimans; N Morgan; C G Mathew; F Arwert
Journal:  Am J Hum Genet       Date:  2000-08-08       Impact factor: 11.025

2.  Evidence for subcomplexes in the Fanconi anemia pathway.

Authors:  Annette L Medhurst; El Houari Laghmani; Jurgen Steltenpool; Miriam Ferrer; Chantal Fontaine; Jan de Groot; Martin A Rooimans; Rik J Scheper; Amom Ruhikanta Meetei; Weidong Wang; Hans Joenje; Johan P de Winter
Journal:  Blood       Date:  2006-05-23       Impact factor: 22.113

3.  Defects of FA/BRCA pathway in lymphoma cell lines.

Authors:  Hui Xiao; Ke Jian Zhang; Bing Xia
Journal:  Int J Hematol       Date:  2008-11-15       Impact factor: 2.490

4.  Subtyping analysis of Fanconi anemia by immunoblotting and retroviral gene transfer.

Authors:  M Pulsipher; G M Kupfer; D Naf; A Suliman; J S Lee; P Jakobs; M Grompe; H Joenje; C Sieff; E Guinan; R Mulligan; A D D'Andrea
Journal:  Mol Med       Date:  1998-07       Impact factor: 6.354

5.  A locus for Fanconi anemia on 16q determined by homozygosity mapping.

Authors:  M Gschwend; O Levran; L Kruglyak; K Ranade; P C Verlander; S Shen; S Faure; J Weissenbach; C Altay; E S Lander; A D Auerbach; D Botstein
Journal:  Am J Hum Genet       Date:  1996-08       Impact factor: 11.025

6.  MxA overexpression reveals a common genetic link in four Fanconi anemia complementation groups.

Authors:  Y Li; H Youssoufian
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

7.  Cloning of the bovine and rat Fanconi anemia group C cDNA.

Authors:  J Ching Ying Wong; N Alon; M Buchwald
Journal:  Mamm Genome       Date:  1997-07       Impact factor: 2.957

8.  Noncomplementation of radiation-induced chromosome aberrations in ataxia-telangiectasia/ataxia-telangiectasia-variant heterodikaryons.

Authors:  M Stumm; K Sperling; R D Wegner
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

9.  The Fanconi anemia group E gene, FANCE, maps to chromosome 6p.

Authors:  Q Waisfisz; K Saar; N V Morgan; C Altay; P A Leegwater; J P de Winter; K Komatsu; G R Evans; R D Wegner; A Reis; H Joenje; F Arwert; C G Mathew; J C Pronk; M Digweed
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

10.  Sequence variation in the Fanconi anemia gene FAA.

Authors:  O Levran; T Erlich; N Magdalena; J J Gregory; S D Batish; P C Verlander; A D Auerbach
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.